Current and Future Pathways in Aspergillus Diagnosis

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Diagnostics

Background:

• Aspergillus fumigatus is a critical priority fungal pathogen identified by the WHO.
• Current diagnostics for aspergillosis often utilize fungal metabolites, including intracellular molecules, cell wall components, and extracellular secretomes.
• Limitations exist in antibody-based diagnostic tests for aspergillosis.

Purpose of the Study:

• To review the shortcomings of antibody tests for aspergillosis diagnosis.
• To highlight the utility of fungal product detection in body fluids.
• To discuss emerging diagnostic approaches for Aspergillus infections.

Main Methods:

• Literature review summarizing current diagnostic strategies for aspergillosis.
• Comparative analysis of antibody tests versus fungal biomarker detection.
• Discussion of specific biomarkers such as beta-D-glucan, galactomannan, and pentraxin 3.
• Exploration of nucleic acid detection, next-generation sequencing, and Aspergillus metallophores.

Main Results:

• Tests detecting fungal products in body fluids show advantages over antibody tests for diagnosing aspergillosis.
• Beta-D-glucan, galactomannan, and pentraxin 3 are highlighted for their application in bronchoalveolar lavage fluids.
• Nucleic acid detection and next-generation sequencing offer promising avenues for improved diagnostics.
• Emerging research on Aspergillus metallophores presents new diagnostic possibilities.

Conclusions:

• Biomarker-based diagnostics targeting fungal products in body fluids are superior to antibody tests for aspergillosis.
• Further research into nucleic acid-based methods and novel biomarkers like metallophores is warranted.
• Improved diagnostic tools are crucial for managing Aspergillus infections, a critical priority pathogen.